Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$114.74
-0.8%		$112.07
$28.66
▼
$126.38
$12.50B0.451.71 million shs964,447 shs
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
$38.21
-0.5%		$41.37
$10.46
▼
$49.70
$5.16B2.232.25 million shs1.97 million shs
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$232.35
-2.5%		$248.25
$128.49
▼
$266.38
$15.47B0.36710,015 shs777,175 shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$138.35
-1.5%		$157.19
$122.14
▼
$186.12
$14.28B0.381.13 million shs1.49 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-0.40%+1.64%+1.54%+32.98%+37.87%
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
+6.19%-2.21%-6.27%-18.40%+259.98%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
+0.14%-1.32%-2.56%-1.12%+87.62%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
+1.47%-2.45%-8.84%-16.67%-1.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$114.74
-0.8%		$112.07
$28.66
▼
$126.38
$12.50B0.451.71 million shs964,447 shs
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
$38.21
-0.5%		$41.37
$10.46
▼
$49.70
$5.16B2.232.25 million shs1.97 million shs
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$232.35
-2.5%		$248.25
$128.49
▼
$266.38
$15.47B0.36710,015 shs777,175 shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$138.35
-1.5%		$157.19
$122.14
▼
$186.12
$14.28B0.381.13 million shs1.49 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-0.40%+1.64%+1.54%+32.98%+37.87%
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
+6.19%-2.21%-6.27%-18.40%+259.98%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
+0.14%-1.32%-2.56%-1.12%+87.62%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
+1.47%-2.45%-8.84%-16.67%-1.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
2.50
Moderate Buy$138.1720.42% Upside
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
3.00
Buy$64.8869.79% Upside
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
3.00
Buy$289.3724.54% Upside
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2.88
Moderate Buy$202.7346.53% Upside

Current Analyst Ratings Breakdown

Latest DFTX, JAZZ, NBIX, and CORT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/29/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$231.00 ➝ $214.00
9/24/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
9/24/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$337.00
9/24/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$337.00
9/18/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$165.00
9/16/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
9/15/2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$64.00 ➝ $78.00
9/15/2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$70.00
9/15/2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$75.00 ➝ $79.00
9/14/2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$75.00
9/14/2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$70.00
(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$761.41M16.29$0.90 per share128.09$6.16 per share18.63
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
N/AN/AN/AN/A$3.36 per shareN/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.27B3.53$15.86 per share14.65$71.07 per share3.27
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$2.86B4.92$4.94 per share28.02$32.63 per share4.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$99.65M$0.42273.2032.97N/A6.52%8.26%6.45%11/4/2026 (Estimated)
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
-$183.79M-$3.43N/AN/AN/AN/A-84.01%-63.66%N/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-$356.15M$14.5016.0210.480.2120.45%33.97%13.02%11/4/2026 (Estimated)
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$478.60M$6.8220.2914.620.6620.91%22.43%15.64%10/27/2026 (Estimated)

Latest DFTX, JAZZ, NBIX, and CORT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/27/2026Q3 2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$2.59N/AN/AN/A$1.04 billionN/A
8/6/2026Q2 2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
-$0.55-$1.44-$0.89-$1.44N/AN/A
8/3/2026Q2 2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$6.18$5.71-$0.47$2.78$1.11 billion$1.21 billion
7/31/2026Q2 2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$1.65$2.85+$1.20$1.39$891.16 million$959.00 million
7/29/2026Q2 2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.0243$0.36+$0.3357$0.36$221.15 million$256.15 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
N/AN/AN/AN/AN/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
2.86
2.77
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
0.04
6.95
6.95
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
0.69
1.78
1.58
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/A
1.87
1.75

Institutional Ownership

CompanyInstitutional Ownership
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
27.91%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
89.14%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
92.59%

Insider Ownership

CompanyInsider Ownership
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.70%
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
2.40%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
4.10%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
730108.10 million85.72 millionOptionable
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
40134.37 million131.14 millionOptionable
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2,89064.92 million62.25 millionOptionable
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2,000101.65 million96.97 millionOptionable

Recent News About These Companies

Neurocrine Biosciences selects Ruder Finn as communications AOR
September 29 at 6:54 PM  |  mmm-online.comM
UBS Group Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price
September 29 at 3:17 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-ubs-group-issues-pessimistic-forecast-for-neurocrine-biosciences-nasdaq-nbix-stock-price-2026-09-29/
Neurocrine Biosciences Reappoints Eiry Roberts As CMO, Keswani Departs
September 29 at 1:53 PM  |  rttnews.comhttps://www.rttnews.com/3694656/neurocrine-biosciences-reappoints-eiry-roberts-as-cmo-keswani-departs.aspx
Neurocrine Biosciences, Inc. annonce des changements au poste de directeur médical
September 29 at 3:52 AM  |  zonebourse.comZ
Neurocrine Biosciences, Inc. Announces Chief Medical Officer Changes
September 28 at 10:52 PM  |  marketscreener.comM
Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer
September 28 at 10:52 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/neurocrine-biosciences-names-eiry-roberts-205654730.html
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
September 28 at 5:48 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/neurocrine-biosciences-appoints-eiry-w-200500435.html
Neurocrine Names Eiry Roberts as New Chief Medical Officer
September 28 at 5:11 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neurocrine-names-eiry-roberts-as-new-chief-medical-officer?utm_source=marketbeat.com&utm_medium=referral
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D.
September 28 at 4:05 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurocrine-biosciences-appoints-eiry-w-roberts-md-as-chief-medical-officer-302891904.html
Neurocrine (NBIX)
September 26 at 8:21 AM  |  es.investing.comhttps://es.investing.com/equities/neurocrine-biosci
Neurocrine (NBIX) Gets a Buy from RBC Capital
September 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NBIX/pressreleases/4791439/neurocrine-nbix-gets-a-buy-from-rbc-capital/
Andra AP fonden Lowers Holdings in Neurocrine Biosciences, Inc. $NBIX
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-andra-ap-fonden-lowers-holdings-in-neurocrine-biosciences-inc-nbix-2026-09-23/
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-neurocrine-maps-ai-china-and-pipeline-strategy-as-ingrezza-faces-2029-price-hit-2026-09-22/
Nykredit A S Makes New $5.19 Million Investment in Neurocrine Biosciences, Inc. $NBIX
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-makes-new-519-million-investment-in-neurocrine-biosciences-inc-nbix-2026-09-22/
RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating
September 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rbc-cuts-price-target-neurocrine-102851283.html
Neurocrine Biosciences stock draws support from strong Q2 figures
September 19, 2026  |  ad-hoc-news.deA
Bank of America Corp DE Buys New Stake in Neurocrine Biosciences, Inc. $NBIX
September 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-buys-new-stake-in-neurocrine-biosciences-inc-nbix-2026-09-19/
Neurocrine Biosciences Director Kevin Charles Increases Stake to 525,636 Shares Following Share Award
September 18, 2026  |  kalkinemedia.comK
CCB Int'l Starts Neurocrine Bio. (NBIX) at Outperform
September 18, 2026  |  streetinsider.comhttps://www.streetinsider.com/New+Coverage/CCB+Intl+Starts+Neurocrine+Bio.+%28NBIX%29+at+Outperform/27077874.html
Mizuho Upgrades Neurocrine Biosciences (NASDAQ:NBIX) to Hold
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-mizuho-upgrades-neurocrine-biosciences-nasdaq-nbix-to-hold-2026-09-18/
Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story
September 18, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/neurocrines-nbix-data-deluge-reshapes-a-familiar-growth-story-1839440/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$114.74 -0.89 (-0.77%)
Closing price 04:00 PM Eastern
Extended Trading
$114.76 +0.03 (+0.02%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Definium Therapeutics stock logo

Definium Therapeutics NASDAQ:DFTX

$38.21 -0.20 (-0.52%)
As of 04:00 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$232.35 -5.93 (-2.49%)
Closing price 04:00 PM Eastern
Extended Trading
$232.36 +0.00 (+0.00%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Neurocrine Biosciences stock logo

Neurocrine Biosciences NASDAQ:NBIX

$138.35 -2.09 (-1.49%)
Closing price 04:00 PM Eastern
Extended Trading
$139.03 +0.68 (+0.49%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas